ANDA 62707, held by Lilly. Tobramycin Sulfate.
As of Nov 16, 2026, ANDA 62707 (Nebcin), held by Lilly, was first approved by FDA on Apr 29, 1987, with 6 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 29, 1987 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| NebcinEQ 10MG BASE/ML ยท injectable;injection | Tobramycin Sulfate | Discontinued |
| Nov 18, 1996 | Supplement 9Manufacturing | Approved | None posted |
| Apr 11, 1996 | Supplement 8Manufacturing | Approved | None posted |
| Mar 27, 1996 | Supplement 7Manufacturing | Approved | None posted |
| Oct 30, 1992 | Supplement 5Manufacturing | Approved | None posted |
| Feb 12, 1992 | Supplement 2Labeling | Approved | None posted |
| Feb 12, 1992 | Supplement 1Labeling | Approved | None posted |
| Apr 29, 1987 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters